We wouldn't give
But if you're
one of the 1
investors who regularly
each month, you
are familiar with the work
of investment writer Dave Sterman.
Much more often
than not, the
value... sometimes by a lot,
|On August 13, 2010, Dave recommended VirnetX Holdings (AMEX: VHC) on the idea that shares of the communications software firm would benefit in a big way from recently litigated and pending patent lawsuits. Over the next 11 months, VirnetX bagged a 543% gain.|
|The following month Dave picked up on gaming industry chatter that a company called Melco Crown Entertainment (Nasdaq: MPEL) was having a good run and picking up market share in Macau. After Dave's report on StreetAuthority.com -- "The Hot Stock in the New Mecca of Gambling" -- Melco gained 250% in 11 months.|
|In January 2011 Dave wrote about an innovative dental laser technology company called BIOLASE Technology (Nasdaq: BLTI). By February the share price hit $3... by early March $4... and by early April share prices jumped to $6.|
And impressive gains aren't the only reason we couldn't wait to see Dave investing $100,000 for us. It's years of experience that fuel these kinds of results.
Dave has worked as an investment analyst for nearly two decades. He's appeared on networks like CNBC and Bloomberg TV. He served as Managing Editor of TheStreet.com and Director of Research at Individual Investor. And before that, he was a Senior Analyst at Smith Barney, where he learned all about the tricks used by Wall Street.
Now, he's the most followed analyst on StreetAuthority.com and he's purchasing his favorite picks for our newest $100,000 real-money portfolio.
Don't miss a single word from StreetAuthority's fastest-rising star.
Simply enter your email address below and for a limited time we'll notify you by email as soon as we publish each new article featuring the picks Dave makes for our new $100,000 real-money portfolio on StreetAuthority.com.